eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2003
vol. 28
 
Share:
Share:
abstract:

The antibodies to beta-2-glycoprotein-I in blood serum and aqueous humor in patients with glaucoma

Agnieszka Szczepanik
,
Ewa Kosior-Jarecka
,
Marek Gerkowicz
,
Maria Kozioł-Montewka
,
Małgorzata Latalska

Centr Eur J Immunol 2003; 28 (4): 143-147
Online publish date: 2004/09/17
View full text Get citation
 
The recent studies tend to consider glaucoma, a leading cause of worldwide blindness, for autoimmunological disorder. The aim of the study was to evaluate frequency of β2-glycoprotein-I antibodies incidence in aqueous humor and serum of glaucoma patients and to estimate the relationship between serum and anterior chamber fluid antibodies in these patients. Samples of blood and anterior chamber fluid were obtained from 21 glaucoma and 27 non glaucoma patients. Incidence of β2-glycoprotein-I antibodies classes IgA and IgG was tested using ELISA method. In the group of glaucoma patients positive ratios were obtained in 8 cases (38%), most frequently in IgA class in aqueous humor (4 cases). The incidence of examined antibodies in anterior chamber fluid was observed in 6 persons (28,5%). In control group positive ratios were observed in 4 cases (15%), most frequently in IgA class in aqueous humor (2 cases). When the ratios were compared between glaucoma and cataract patients, statistically significant differences between β2-glycoprotein-I antibodies class IgA in aqueous humor (p=0.0031) and in serum (p= 0.0005) were observed. The data indicate possible participation of β2-glycoprotein-I antibodies in pathogenesis of glaucoma, yet to determine their pathological and clinical significance further studies are necessary.
keywords:

glaucoma, antiphospholipid antibodies


Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.